Loading…
Computer analysis and identification of antigenic determinants from five glycoproteins of HSV2 (155.17)
To screen the antigenic determinants from glycoprotein B (gB2), C (gC2), E (gE2), G (gG2) and I (gI2) of herpes simplex virus II (HSV2) for designing novel vaacine, the aminao acid sequences of the five proteins were analysed with several software algorithms, DNAstar, Biosun, and Antheprot. The comm...
Saved in:
Published in: | The Journal of immunology (1950) 2011-04, Vol.186 (1_Supplement), p.155-155.17 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | To screen the antigenic determinants from glycoprotein B (gB2), C (gC2), E (gE2), G (gG2) and I (gI2) of herpes simplex virus II (HSV2) for designing novel vaacine, the aminao acid sequences of the five proteins were analysed with several software algorithms, DNAstar, Biosun, and Antheprot. The common antigenic determinants screened by all the software algorithms were synthesized chenically and identified by animal immune experiments. Sixteen synthesized antigenic determinants selected from the five proteins were linked to carrier protein BSA respectively to enhance their immunogenicity, and uesed as immunogens to immunize mice. The antibodies in the sera of the immunized mice were detected with the coreesponding immunogens and the parent glycoproteins by EIA and western blotting. The virus-neutralizing activity of the antisera were tested with vero cell in vitro. The antisera reacted strongly with the parent glycoproteins, and also the peptides reacted strongly with antibodies against the parent glycoproteins. The antisera against five antigenic determinants from gB2 ,gC2, gE2, gG2, and gI2 can neutralize HSV2 infectivity in vitro respectively, which has not been reported up to now. These results suggested that the antigenic determinants from the five glycoproteins screened by software algorithms and validated by experiments are promising for vaccine design. |
---|---|
ISSN: | 0022-1767 1550-6606 |
DOI: | 10.4049/jimmunol.186.Supp.155.17 |